Recently stock market analysts have updated their consensus ratings on shares of BioScrip, Inc. (NASDAQ:BIOS). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

08/12/2015 – BioScrip, Inc. had its “buy” rating reiterated by analysts at Dougherty & Co. They now have a USD 4 price target on the stock.

08/11/2015 – BioScrip, Inc. was downgraded to “neutral” by analysts at SunTrust. They now have a USD 2 price target on the stock.

05/20/2015 – BioScrip, Inc. had its “outperform” rating reiterated by analysts at Barrington Research. They now have a USD 6 price target on the stock.

05/08/2015 – BioScrip, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 6.5 price target on the stock.

05/04/2015 – BioScrip, Inc. was upgraded to “hold” by analysts at Zacks.

02/27/2014 – BioScrip, Inc. was downgraded to “neutral” by analysts at Sidoti.

11/08/2013 – BioScrip, Inc. had its “buy” rating reiterated by analysts at Noble Financial. They now have a USD 11 price target on the stock.

11/08/2013 – BioScrip, Inc. was downgraded to “buy” by analysts at Feltl & Co.. They now have a USD 7.5 price target on the stock.

BioScrip, Inc. has a 50 day moving average of 2.38 and a 200 day moving average of 2.05. The stock’s market capitalization is 182.87M, it has a 52-week low of 1.19 and a 52-week high of 4.11.

The share price of the company (NASDAQ:BIOS) was up +4.31% during the last trading session, with a high of 2.75 and the volume of BioScrip, Inc. shares traded was 287522.

View other investors thoughts on BioScrip, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.